Results 121 to 130 of about 116,902 (309)

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging

open access: yesEJNMMI Radiopharmacy and Chemistry
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising class of therapeutics, particularly in the treatment of cancers with defective DNA repair mechanisms, such as those with breast cancer genes (BRCA) mutations.
Gianluca Destro   +4 more
doaj   +1 more source

A poli(ADP-ribóz) polimeráz 2 (PARP-2) metabolizmusban betöltött szerepe HepG2 sejtekben

open access: yes, 2011
A poli(ADP)-ribóz polimeráz 2 (PARP-2) egy a 17 eddig felfedezett PARP enzim közül, melyekhez sok biológiai szerep rendelhető, mint például a DNS hibajavítás, spermatogenezis, gyulladásos folyamatok, metabolizmus.
Hollós, Patrik
core  

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

open access: yesChemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias   +9 more
wiley   +1 more source

A PARP inhibitorok hatásának vizsgálata humán keratinociták differenciációjára

open access: yes
A poli(ADP-riboz)iláció egy poszttranszlációs fehérje módosítás, amelyet a poli(ADP-ribóz) polimeráz (PARP) enzimek végeznek. A PARP aktivitás számos biológiai folyamat szabályozásában szerepel, többek között a DNS hibajavítás, transzkripció és ...
Maczkó, Eszter
core  

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher   +12 more
wiley   +1 more source

Mono-methylated histones control PARP-1 in chromatin and transcription

open access: yeseLife
PARP-1 is central to transcriptional regulation under both normal and stress conditions, with the governing mechanisms yet to be fully understood. Our biochemical and ChIP-seq-based analyses showed that PARP-1 binds specifically to active histone marks ...
Gbolahan Bamgbose   +3 more
doaj   +1 more source

Incorporating PARP Inhibition in Cancer Therapy: Key Questions, Expert Answers

open access: yes, 2015
This engaging symposium focussed on the rationale and current evidence supporting the role for poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with cancer.
Eric Van Cutsem   +5 more
core  

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting

open access: yes, 2017
Poly(ADP-ribose) polymerases have shown true promise in early clinical studies due to reported activity in BRCA-associated cancers. PARP inhibitors may represent a potentially important new class of chemotherapeutic agents directed at targeting cancers ...
Karolina N. Dziadkowiec   +3 more
core   +1 more source

Aloe vera in Food Preservation: Harnessing Bioactive Constituents for Clean‐Label Innovation and Safety Assurance

open access: yesFood Safety and Health, EarlyView.
Aloe vera‐derived biopolymers and nanoformulations enhance antimicrobial, antioxidant, and barrier functions in clean‐label edible coatings and films, whereas safety‐critical anthraquinone thresholds and regulatory constraints shape their translational potential.
Acharya Balkrishna   +6 more
wiley   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

open access: yesPeriodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy